On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
- MHLW Pharma Bureau Chief Tarumi Tapped to Lead Coronavirus Reponses, Mitsuaki Kamata to Take Over
March 25, 2020
- Drug Pricing Rules to Be Applied to Zolgensma: Chuikyo
March 25, 2020
- Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
- Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
- Japan’s First Ophthalmology Regenerative Medicine Product Approved: J-TEC
March 23, 2020
- Japan Eases 30-Day Inspection Rules to Expedite Coronavirus Trials
March 23, 2020
- MHLW Issues COVID-19 Treatment Guide
March 19, 2020
- Increase Copay for OTC-Like Drugs under New Mixed-Care Scheme: Professor
March 19, 2020
- 3 Key Antibiotics to Receive Price Raises through Unprofitability Re-Pricing
March 18, 2020
- Japan Grants Orphan Status to 7 Drugs
March 18, 2020
- Japan’s Avigan Stockpile for Some 2 Million People; No Plan for Increase: Govt
March 18, 2020
- Health Minister Reiterates Support for COVID-19 Drug Development; MHLW Accelerating Rollout of Quick Testing
March 18, 2020
- Japan to Launch Panel on Stable Drug Supplies after Cefazolin Woes; Coronavirus Outbreak Possibly Up for Discussion
March 17, 2020
- Revised Special Flu Law Enforced; Japan Can Now Declare Emergency over COVID-19
March 16, 2020
- Japan, US Agree to Work Together to Develop COVID-19 Treatments: Abe
March 16, 2020
- Japan Enacts State of Emergency Bill over Coronavirus
March 13, 2020
- Japan’s Stance to Look at Overseas Examples for Copay Raises Called into Question
March 13, 2020
- PMDA Prepares “Special Leave” System for Coronavirus Infected Staffers
March 13, 2020
- Annual Drug Price Revisions “Practically Feasible”: Health Policy Advisor
March 12, 2020
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…